Engineered Biomaterials for Cardiovascular Implants

描述(由申请人提供)： 对心血管衰竭认识的最新进展 植入物让科学界和工业界都在寻找 提供最佳产品的替代方案。在过去的十年里，迅速 细胞和分子生物学方法的进步导致了显著的 扩展我们在血管生物学方面的知识库，这可能会 应用于心血管外科和植入物设计的各个领域。在……里面 认识到细胞生理学、分子生物学和 其他生物医学科学在改善植入物性能、研究和 心血管植入科学和工程方面的发展努力 最近专注于开发工程生物杂化生物材料，利用 合成生物材料以及细胞、生物化学物质和细胞外 心血管组织基质将发展新一代心血管 植入物和相关产品具有更具体和更长期的 性能目标比目前市场上的产品更高。这个 拟议的工作重点是开发和应用生物杂交技术 人造血管移植物。拟议研究的总体目标：发展和 评估以下四种生物混合技术，以提高其性能 目前使用特定植入物和动物模型的合成血管移植物 主要研究内容有：1)生物活性生物材料表面改性； 2)生物活性可降解水凝胶；以及3)局部药物/基因递送系统和 治疗。假设：上述b1混合技术，即 生物活性生物材料表面改性，生物活性可降解水凝胶， 而当地的药物/基因输送系统S/疗法将促进显著的收益 在人造血管移植物的长期性能方面。这些元素的组合 应用技术将协同工作，最大限度地提高嫁接性能。 目标：1)对ePTFE(膨体)进行生物活性表面改性 聚四氟乙烯)血管移植物，评估其对种植体的影响 体内性能；2)开发可降解的水凝胶配方 EPTFE微孔植入促进血管生成的实验研究 在种植体周围的宿主组织中，ePTFE移植物的新生血管 新生血管跨壁生长的管壁和管腔内皮化 组织；3)开发可降解的水凝胶输送工具，可以 植入ePTFE移植物用于局部药物/基因靶向移植物治疗 以及4)比较生物杂交组合的影响。 将技术的性能移植到单一的技术方法。 总体而言，拟议的工作将定义有希望的生物杂交技术 用于临床应用，并将为进一步的技术奠定基础 发展。(摘要结束)

DESCRIPTION (provided by applicant): Recent developments in the understanding of the failure of cardiovascular implants has led both the scientific and industrial communities searching for alternatives to provide optimum products. Over the past ten years, rapid advances in cell and molecular biology methodologies have led to a significant expansion of our knowledge base in vascular biology which potentially has application in every area of cardiovascular surgery and implant design. In recognition of the critical role that cell physiology, molecular biology, and other biomedical sciences play in improving implant performance, research and development efforts in cardiovascular implant science and engineering have recently focused on developing engineered biohybrid biomaterials that utilize synthetic biomaterials as well as cells, biochemicals, and extracellular matrix of cardiovascular tissues to develop a new generation of cardiovascular implants and related products that have more specific and longer-term performance goals than products that are currently on the market. The proposed work focuses on developing and applying biohybrid technologies for synthetic vascular grafts. Overall goal of the proposed study: Develop and evaluate the following four biohybrid technologies for improved performance of synthetic vascular grafts using specific implants and animal models currently under investigation by the PI: 1) bioactive biomaterial surface modifications; 2) bioactive degradable hydrogels; and 3) local drug/gene delivery systems and therapies. Hypotheses: The above described b1ohybrid technologies, namely bioactive biomaterial surface modifications, bioactive degradable hydrogels, and local drug/gene delivery system s/therapies will promote significant gains in long-term performance of synthetic vascular grafts. Combinations of these applied technologies will work in synergy to maximize graft performance. Aims: 1) Develop bioactive surface modifications on ePTFE (expanded polytetrafluoroethylene) vascular grafts and assess their effects on implant performance in vivo; 2) Develop degradable hydrogel formulations that can be impregnated into the porous space of ePTFE grafts for promoting angiogenesis in host tissues surrounding the implant, neovascularization of the ePTFE graft wall and luminal endothelialization via transmural growth of neovascular tissue; 3) Develop degradable hydrogel delivery vehicles that can be impregnated into ePTFE grafts for local drug/gene therapies targeting graft hyperplasia; and 4) Compare the impact of combinations of biohybrid technologies on graft performance to single technology approaches. Overall the proposed work will define biohybrid technologies that have promise for clinical application and will set the stage for further technology development. (End of Abstract)